High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The outbreak and rapid spread of SARS-CoV-2 virus has led to a dire global pandemic with millions of people infected and ~ 400,000 deaths thus far. Highly accurate detection of antibodies for COVID-19 is an indispensable part of the effort to combat the pandemic 1,2 . Here we developed two-plex antibody detection against SARS-CoV-2 spike proteins 3 (the S1 subunit and receptor binding domain RBD) in human serum and saliva on a near-infrared nano-plasmonic gold (pGOLD) platform 4–8 . By testing nearly 600 serum samples, pGOLD COVID-19 assay achieved ~ 99.78 % specificity for detecting both IgG and IgM with 100 % sensitivity in sera collected > 14 days post disease symptom onset, with zero cross-reactivity to other diseases. Two-plex correlation analysis revealed higher binding of serum IgM to RBD than to S1. IgG antibody avidity toward multiple antigens were measured, shedding light on antibody maturation in COVID-19 patients and affording a powerful tool for differentiating recent from remote infections and identifying re-infection by SARS-CoV-2. Just as important, due to high analytical sensitivity, the pGOLD COVID-19 assay detected minute amounts of antibodies in human saliva, offering the first non-invasive detection of SARS-CoV-2 antibodies.
Article activity feed
-
SciScore for 10.1101/2020.06.16.155580: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 3) Secondary antibody incubation: each well was subsequently incubated with a mixture of 4 nM IRDye800-labeled anti-human IgG secondary antibody, 4 nM CF-647-labeled anti-human IgM secondary antibody, and 6 nM CF-647-labeled streptavidin for 30 minutes at room temperature (Fig. 1a). anti-human IgGsuggested: Noneanti-human IgMsuggested: NoneSoftware and Algorithms Sentences Resources Cutoffs were determined by ROC curve analysis using MedCalc Statistical Software version 19.2.1 (MedCalc Software … SciScore for 10.1101/2020.06.16.155580: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 3) Secondary antibody incubation: each well was subsequently incubated with a mixture of 4 nM IRDye800-labeled anti-human IgG secondary antibody, 4 nM CF-647-labeled anti-human IgM secondary antibody, and 6 nM CF-647-labeled streptavidin for 30 minutes at room temperature (Fig. 1a). anti-human IgGsuggested: Noneanti-human IgMsuggested: NoneSoftware and Algorithms Sentences Resources Cutoffs were determined by ROC curve analysis using MedCalc Statistical Software version 19.2.1 (MedCalc Software Ltd., Ostend, Belgium). MedCalcsuggested: (MedCalc, RRID:SCR_015044)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
